It was also suggested that CAR-T cells targeting CD19 induced B precursor acute lymphoblastic leukemia lineage switch towards a more plastic state (61), suggesting the potential of combining therapies targeting cancer stem cells with CART19 or blinatumomab in restoring the sensitivity of cancer cells to anti-CD19 drugs. The gene discussed is CD19; the disease is cancer.